Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.46 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.46 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.46 |
| ▸ | DHODH | Q02127 | 2/20 | 0.44 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3203228 | 0.95 | CYP4F2 (0.47) | HDAC6LOXL2CYP4F2CYP4A11DHODH | |
| SCHEMBL3216494 | 0.86 | RXFP1 (0.58) | HDAC6LOXL2TRPA1ABHD6RXFP1 | |
| SCHEMBL3012713 | 0.77 | LOXL2 (0.76) | LOXL2CYP4F2CYP4A11DHODHSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL4447485 | 0.75 | LOXL2 (0.73) | LOXL2CYP4F2CYP4A11DHODHSMN1; SMN2 | |
| SCHEMBL5725416 | 0.72 | CYP4A11 (0.73) | LOXL2CYP4F2CYP4A11DHODHSMN1; SMN2 | |
| SCHEMBL20302834 | 0.71 | MAPT (0.54) | LOXL2TRPA1ABHD6KMT2AMEN1 | |
| SCHEMBL24426597 | 0.71 | CYP4A11 (0.76) | LOXL2CYP4F2CYP4A11DHODHSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL5725413 | 0.71 | CYP4A11 (0.71) | LOXL2CYP4F2CYP4A11DHODHSMN1; SMN2 | |
| SCHEMBL19889923 | 0.70 | CYP4F2 (0.74) | HDAC6LOXL2CYP4F2CYP4A11DHODH | |
| SCHEMBL70173 | 0.69 | CYP4F2 (0.83) | LOXL2CYP4F2CYP4A11DHODHSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8557798-B2 | Macrocyclic heterocyclic aspartyl protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-10-15 | — | — | US | disclosed |
| US-7812013-B2 | Macrocyclic heterocyclic aspartyl protease inhibitors | SCHERING CORPORATION (US) | 2010-10-12 | — | — | US | disclosed |
| US-20100063121-A1 | Macrocyclic Heterocyclic Aspartyl Protease Inhibitors | SCHERING CORPORATION | 2010-03-11 | — | — | US | disclosed |
| US-20060281729-A1 | Macrocyclic heterocyclic aspartyl protease inhibitors | SCHERING CORPORATION | 2006-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063121-A1 | Macrocyclic Heterocyclic Aspartyl Protease Inhibitors | CHRM1, CHRM2, CHRM5 | HDAC6 2392/4885LOXL2 3417/4885CYP4F2 2801/4885 |
| US-20060281729-A1 | Macrocyclic heterocyclic aspartyl protease inhibitors | CHRM1, CHRM2, CHRM5 | HDAC6 2392/4885LOXL2 3417/4885CYP4F2 2801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.